CAS: 2254706-21-1
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | CVN424 REF: 54-BUP03282CAS: 2254706-21-1 | ≥98% | 925.00 €~1,646.00 € | Tue 06 May 25 |
 | CVN424 REF: TM-T9346CAS: 2254706-21-1 | 99.02% | 96.00 €~1,216.00 € | Mon 12 May 25 |
 | CVN424 REF: 3D-EQD70621CAS: 2254706-21-1 | Min. 95% | To inquire | Mon 16 Jun 25 |
Ref: 54-BUP03282
| 25mg | 925.00 € | ||
| 50mg | 1,216.00 € | ||
| 100mg | 1,646.00 € |
Estimated delivery in United States, on Tuesday 6 May 2025
CVN424
CAS:2254706-21-1
CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.
Formula:
C24H29F2N5O3
Purity:
99.02%
Color and Shape:
Solid
Molecular weight:
473.52
Ref: TM-T9346
| 1mg | 96.00 € | ||
| 5mg | 243.00 € | ||
| 10mg | 376.00 € | ||
| 25mg | 630.00 € | ||
| 50mg | 898.00 € | ||
| 100mg | 1,216.00 € | ||
| 1mL*10mM (DMSO) | 253.00 € |
Estimated delivery in United States, on Monday 12 May 2025
CVN424
CAS:2254706-21-1
Please enquire for more information about CVN424 including the price, delivery time and more detailed …
Formula:
C24H29F2N5O3
Purity:
Min. 95%
Molecular weight:
473.5 g/mol
Ref: 3D-EQD70621
| 10mg | 977.00 € | ||
| 25mg | 1,501.00 € | ||
| 50mg | 2,339.00 € |
Estimated delivery in United States, on Monday 16 Jun 2025
